Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation.
Growth plate abnormalities, associated with impaired hypertrophic chondrocyte apoptosis, are observed in humans and animals with abnormalities of vitamin D action and renal phosphate reabsorption. Low circulating phosphate levels impair hypertrophic chondrocyte apoptosis, whereas treatment of these cells with phosphate activates the mitochondrial apoptotic pathway. Because phosphate-mediated apoptosis of chondrocytes is differentiation-dependent, studies were performed to identify factors that contribute to hypertrophic chondrocyte apoptosis. An increase in the percentage of cells with low mitochondrial membrane potential, evaluated by JC-1 fluorescence, was observed during hypertrophic differentiation of primary murine chondrocytes in culture. This percentage was further increased by treatment of hypertrophic, but not proliferative, chondrocytes with phosphate. Phosphate-mediated apoptosis was observed as early as 30 min post-treatment and was dependent upon Erk1/2 phosphorylation. Inhibition of Erk1/2 phosphorylation in vivo confirmed an important role for this signaling pathway in regulating hypertrophic chondrocyte apoptosis in growing mice. Murine embryonic metatarsals cultured under phosphate-restricted conditions demonstrated a 2.5-fold increase in parathyroid hormone-related protein mRNA expression accompanied by a marked attenuation in phospho-Erk immunoreactivity in hypertrophic chondrocytes. Thus, these investigations point to an important role for phosphate in regulating mitochondrial membrane potential in hypertrophic chondrocytes and growth plate maturation by the parathyroid hormone-related protein signaling pathway.
Miedlich
Susanne U
SU
Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Zalutskaya
Alena
A
Zhu
Eric D
ED
Demay
Marie B
MB
D000818:Animals; D017209:Apoptosis; D049109:Cell Proliferation; D002478:Cells, Cultured; D019902:Chondrocytes / Q000378:metabolism*; D005434:Flow Cytometry / Q000379:methods; D006984:Hypertrophy / Q000473:pathology; D008564:Membrane Potentials; D051379:Mice; D008810:Mice, Inbred C57BL; D008928:Mitochondria / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D010710:Phosphates / Q000737:chemistry*; D010766:Phosphorylation; D020133:Reverse Transcriptase Polymerase Chain Reaction
D010710:Phosphates; D048052:Mitogen-Activated Protein Kinase 3
J Bone Miner Res. 2003 Aug;18(8):1430-42
12929932
Mol Cell Biol. 2008 Jan;28(1):344-57
17967876
Am J Physiol Regul Integr Comp Physiol. 2004 Aug;287(2):R328-35
15072963
Endocrinology. 2002 Aug;143(8):3179-82
12130585
J Cell Physiol. 2007 Mar;210(3):609-15
17133357
Am J Hum Genet. 2006 Feb;78(2):179-92
16358214
Matrix Biol. 1994 Aug;14(4):329-35
7827756
J Biol Chem. 2008 Sep 26;283(39):26499-508
18632667
Methods. 2001 Dec;25(4):402-8
11846609
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9637-42
15976027
Endocrinology. 1996 Nov;137(11):5055-67
8895380
J Cell Physiol. 2007 Sep;212(3):591-9
17443683
Bone. 2007 Jul;41(1):13-8
17466614
J Bone Miner Res. 2003 Apr;18(4):662-8
12674327
Am J Physiol Cell Physiol. 2001 Sep;281(3):C833-9
11502560
Endocrinology. 2002 Apr;143(4):1467-74
11897705
Endocrinology. 2007 Feb;148(2):530-7
17068135
Endocrinology. 2002 Sep;143(9):3691-4
12193585
Bone. 2001 Jan;28(1):1-8
11165936
J Cell Biochem. 2009 Oct 15;108(3):668-74
19681042
J Cell Biol. 1997 Jan 13;136(1):205-13
9008714